Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis

BACKGROUND: Many clinical trials have shown the efficacy of aromatase inhibitors (AIs) in the management of breast cancer (BC). There is growing evidence that CYP19A1 single-nucleotide polymorphisms (SNPs) are associated with clinical response (CR) and adverse effects (AEs) among BC patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Artigalás, Osvaldo, Vanni, Tazio, Hutz, Mara Helena, Ashton-Prolla, Patricia, Schwartz, Ida Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475294/
https://www.ncbi.nlm.nih.gov/pubmed/26067721
http://dx.doi.org/10.1186/s12916-015-0373-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475294/
https://www.ncbi.nlm.nih.gov/pubmed/26067721
http://dx.doi.org/10.1186/s12916-015-0373-9

Ejemplares similares